RxDoctor Payments Data

John Blomstedt, DO

Dermatology · Scottsbluff, NENPI 1538382528

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 38.8% of the total. That places this record below the midpoint for dermatology clinicians in NE, where the typical reported total is $2,089.

$1,915in general payments, 2019–2025

Across 106 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$743
  • Amgen$263
  • E.r. Squibb & Sons, L.L.C.$195
  • Pfizer$159
  • Bristol Myers Squibb$115
  • Johnson & Johnson$109
  • plus $331 from 8 others

What the payments were for

  • Food & beverage$1,915100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,915 in reported general payments places this provider in the 45th percentile of 68 dermatology providers in Nebraska.

See all dermatology providers in Nebraska

Medicare billing

Part B allowed, 2024
$335,327
Medicare patients
1,271
Services billed
6,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab46$424,335
OtezlaApremilast27$133,868
Ketoconazole227$5,955
Clobetasol Propionate90$5,704
Clindamycin Phosphate167$4,154
Metronidazole60$3,980
Triamcinolone Acetonide315$3,894
Betamethasone Dipropionate61$3,138
Doxycycline Hyclate92$2,055
Fluorouracil21$1,798
Azelaic Acid16$793
Spironolactone79$694
Fluocinonide30$680
Ammonium Lactate34$670
MethotrexateMethotrexate Sodium43$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$263$133,86827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 68 dermatology providers in Nebraska.

Other dermatology in Scottsbluff

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →